CA0078

CA0078 is a small molecule Janus kinase (JAK) inhibitor being developed by Protheragen. It is currently in Phase I clinical development for the treatment of inflammatory and autoimmune conditions, specifically osteoarthritis and psoriasis. By inhibiting the JAK family of enzymes, the drug interferes with the JAK-STAT signaling pathway, which is a central communication node for numerous cytokines and growth factors involved in inflammation and tissue degradation. In the context of osteoarthritis, it aims to reduce joint inflammation and cartilage breakdown, while in psoriasis, it targets the systemic and local inflammatory processes that lead to skin lesions.